Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA)
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
http://link.springer.com/article/10.1007/s00280-018-3716-3/fulltext.html
Reference24 articles.
1. Kauhava L, Immonen-Räihä P, Parvinen I, Holli K, Pylkkänen L, Kaljonen A, Helenius H, Kronqvist P, Klemi PJ (2008) Lower recurrence risk through mammographic screening reduces breast cancer treatment costs. Breast 17:550–554
2. Spicer DV, Pike MC (1993) Breast cancer prevention through modulation of endogenous hormones. Breast Cancer Res Treat 28:179–193
3. Beslija S, Bonneterre J, Burstein HJ et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20:1771–1785
4. Chandarlapaty S, Chen D, He W et al (2016) Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol 2:1310–1315
5. Puyang X, Furman C, Zheng GZ et al (2018) Discovery of selective estrogen receptor covalent antagonists for the treatment of ERαWT and ERαMUT breast cancer. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-17-1229
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions;Cancers;2024-01-27
2. Research progress on tamoxifen and its analogs associated with nuclear receptors;Future Medicinal Chemistry;2023-08
3. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges;Journal of Medicinal Chemistry;2023-06-28
4. Separate Evaluation of Fraction Absorbed and Intestinal Availability after Oral Administration of Drugs Based on the Measurement of Portal and Systemic Plasma Concentrations and Luminal Concentration;Molecular Pharmaceutics;2023-03-14
5. Indazole as a privileged scaffold in drug discovery;Privileged Scaffolds in Drug Discovery;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3